Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Ingalls Industries Inc (HII) vs Revvity Inc (RVTY) Price & Performance

Huntington Ingalls Industries IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Huntington Ingalls Industries Inc vs Revvity Inc — how do they compare? Huntington Ingalls Industries Inc trades at $326 (market cap $12.92B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Huntington Ingalls Industries Inc and Revvity Inc are close in size by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.68%). Which is the better fit depends on your goals.

HIIRVTY
Market Cap
$12.92B$12.91B
Sector
TechnologyTechnology
52-Week High
$453.73$117.75
52-Week Low
$265.40$82.26
Enterprise Value
$15.84B$15.23B
Dividend Yield
1.68%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Ingalls Industries Inc

HII trades at $326.80, down 1.21% over the past day, with a bullish technical outlook supported by moving averages and key support at $326. The company reported strong Q2 2026 earnings of $5.27 EPS, beating estimates, with revenue growth of 10.9% year-over-year. Recent contract awards, including a $2.2 billion task order for surveillance and intelligence capabilities, highlight ongoing government demand. Valuation metrics show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

The investment outlook is positive, driven by robust defense contracts and operational improvements, with a consensus price target of $359.67 suggesting 10% upside. Risks include dependence on U.S. military spending and potential political headwinds affecting naval budgets. Analyst sentiment is mixed but leans bullish, with 44% buy ratings. Overall, HII presents a solid opportunity in the defense sector, though investors should monitor contract execution and macroeconomic factors.

Revvity Inc

RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.

The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY